SCHEMBL3455952

SCHEMBL3455952

O=C(Cl)c1nnn(-c2ccccc2F)c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 3/20 0.43
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TNKS2 Q9H2K2 1/20 0.39
MAPK14 Q16539 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CNR2 P34972 1/20 0.38
CA4 P22748 1/20 0.38
CA9 Q16790 1/20 0.38
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3753122 0.89 ALDH1A1 (0.56) ALDH1A1GAANPSR1POLBKDM4E
SCHEMBL3456117 0.81 ALDH1A1 (0.49) ALDH1A1GAANPSR1POLBKDM4E
SCHEMBL3457178 0.78 IDH1 (0.48) ALDH1A1GAANPSR1POLBKDM4E
SCHEMBL20405667 0.77 ALDH1A1 (0.42) ALDH1A1GAANPSR1POLBCNR2
SCHEMBL4501747 0.76 NPC1 (0.55) ALDH1A1GAAPOLBKDM4EMAPT
SCHEMBL13765570 0.75 MEN1 (0.47) ALDH1A1NPSR1POLBCA1CA2
SCHEMBL2219241 0.72 HTT (0.65) NPSR1MAPT
SCHEMBL30038081 0.72 HTT (0.65) NPSR1MAPT
SCHEMBL3455982 0.72 CA1 (0.58) ALDH1A1GAAPOLBKDM4ETNKS2
SCHEMBL3455838 0.72 ALDH1A1 (0.57) ALDH1A1GAANPSR1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
CN-101918395-B Triazole oxadiazole derivatives MERCK SERONO SA 2014-04-16 CN disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
EP-2250165-A1 TRIAZOLE OXADIAZOLES DERIVATIVES Merck Serono S.A. (CH) 2010-11-17 EP disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 ALDH1A1 466/4885GAA 4078/4885NPSR1 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.